Zacks.com on MSN2d
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesGSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for ...
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding.
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback